2018 Press Releases

DateTitle
December 06, 2018FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors
November 08, 2018FibroGen Reports Third Quarter 2018 Financial Results
November 02, 2018FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018
October 30, 2018ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
October 25, 2018FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting
October 16, 2018FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting
October 01, 2018Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
September 12, 2018FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
August 07, 2018FibroGen Reports Second Quarter 2018 Financial Results
August 01, 2018FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
June 07, 2018FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease
June 04, 2018FibroGen to Present at Two Upcoming Investor Conferences
June 03, 2018FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting
May 31, 2018Astellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia
May 21, 2018FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018
May 09, 2018FibroGen Reports First Quarter 2018 Financial Results
May 02, 2018FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018
March 01, 2018FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
February 27, 2018FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results
February 21, 2018FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018